Fibromyalgia Therapeutics Market Size, Share, And Growth Report 2032

Fibromyalgia Therapeutics Market Size

The global Fibromyalgia Therapeutics market size was worth around USD 2.74 billion in 2023 and is predicted to grow to around USD 4.00 billion by 2032 with a compound annual growth rate (CAGR) of roughly 4.3% between 2024 and 2032.

The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD billion). The report covers a forecast and an analysis of the Fibromyalgia Therapeutics market on a global and regional level.

Request Free Sample

Fibromyalgia Therapeutics Market: Overview

Fibromyalgia is a disease that causes muscle pain and exhaustion. In the event of fibromyalgia, psychiatric illnesses are progressively common, and with the growing occurrence rate, post-traumatic stress disorders are also seen. In patients with fibromyalgia, screening for symptoms of post-traumatic stress disorders is also an important component of the evaluation process.

In-depth secondary research is used to ascertain overall market size, top industry players, top products, industry associations, etc. Macro-economic indicators such as healthcare industry outlook, healthcare spending, research funding, GDP along with company websites, company annual reports, white papers, financial reports, and other sources have also been considered to arrive at the indicated market numbers.

The study also includes drivers and restraints for the fibromyalgia therapeutics along with the impact they have on the demand over the forecast period. Besides, the report includes the study of opportunities and trends available in the fibromyalgia therapeutics market on a global level. It is observed that the increasing incidents of traumatic stress and road accidents are the main driving factor of the therapy industry for fibromyalgia. Research released in the Pain Research and Management Journal discovered that fibromyalgia syndrome followed physical trauma in 2014. It was discovered that 8 percent of people experienced extensive chronic pain in the research, performed with a particular cohort of people engaged in motor car accidents. The research also showed the incidence rate of fibromyalgia in Israel victims of a 15 percent train crash.

Request Free Sample

Fibromyalgia Therapeutics Market: Segmentation

The study provides a decisive view of the fibromyalgia therapeutics market by segmenting the market based on drug class, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2024 to 2032.

On the basis of drug class, the fibromyalgia therapeutics market is segmented into antidepressants, antiepileptics, muscle relaxants, analgesics, and other drugs. Antidepressant drugs are majorly used for fibromyalgia treatment. These medicines help to comfort the fatigue and pain associated with the disorder.  The antiepileptic drugs segment accounted for a large share of the fibromyalgia therapeutics market in 2023. Gabapentin and Pregabalin are the major antiepileptic drugs prescribed for fibromyalgia treatment.

By distribution channel, the fibromyalgia therapeutics market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy accounted for a larger share of the fibromyalgia therapeutics market. Online pharmacy is likely to register a high CAGR in the global market.

Fibromyalgia Therapeutics Market: Report Scope

Fibromyalgia Therapeutics Market: Regional Analysis

Regional segmentation includes the current and forecast demand for the Asia Pacific, North America, Latin America, Europe, and Middle East & Africa with its further bifurcation into major countries. 

North America, Asia-Pacific, Latin America, Middle East & Africa, and Europe are key regional segments of fibromyalgia therapeutics market. North America dominated the fibromyalgia therapeutics market in 2023. The rising prevalence of chronic rheumatic diseases and growing healthcare expenditure are some of the major factors propelling the growth of market in this region. According to the 2017 stats proposed by the Centers for Disease Control and Prevention (CDC), about 54.4 million adolescents in the U.S. have arthritis i.e. about 25% of the population. It is also noted that arthritis is expected to reach in the U.S. to nearly 78 million adolescents, aged 18 years or older, by 2040. Some of the variables that fuel the North American market are also the presence of extremely developed technology, increasing numbers of chronic pain illnesses owing to evolving lifestyle. In addition, growth in the ageing population base, the presence of promising healthcare systems mentioned by government agencies, increased awareness among the population are further driving market growth in this region.

Fibromyalgia Therapeutics Market: Competitive Players

The report also provides a company market share analysis in order to give a broader view of the key players in the market. Industry insights and information is delivered in the required format. ZMR develops a list of industry players (manufacturers), distributors, retailers, and industry experts.

• Pfizer Inc.
• Eli Lilly
• and Company
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Allergan Plc
• Aptinyx Inc.
• Astellas Pharma Inc.
• Innovative Med Concepts Inc.
• Prismic Pharmaceuticals Inc.
• Intec Pharma Ltd.
• Sanofi
• Bayer AG.

The Global Fibromyalgia Therapeutics Market is segmented as follows:

Global Fibromyalgia Therapeutics Market: Drug Class Segment Analysis

• Antidepressants (Duloxetine, Milnacipran, and Other Drugs)
• Antiepileptic’s  (Gabapentin, Pregabalin, and Other Drugs)
• Muscle Relaxants
• Analgesics
• Other Drugs

Global Fibromyalgia Therapeutics Market: Distribution Channel Segment

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Fibromyalgia Therapeutics Market: Regional Segment Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa